| Literature DB >> 24756073 |
Zhe-Han Yang1, Ying Zhuo1, Ya-Qin Chai1, Ruo Yuan1.
Abstract
Accurate prediction of a particular cancer can be achieved by measuring multiplex biomarkers. Traditional methods for multi-biomarkers detection are either multi-spots assay with chip or multi-label assay with one detection spot. However, the detection throughput of these two approaches is limited by the substrate area and the numbers of available label respectively. To solve this problem, in the present study, an immunoassay was firstly prepared by combining multi-label strategy and multi-spot assay with a novel array electrode for simultaneous detection of six biomarkers for hepatocellular carcinoma (HCC). The detection throughput of the proposed method was doubled in comparison with traditional multi-spots assay (one target protein was detected on each analytic spot), which could greatly enhance the sensitivity and specificity of HCC diagnosis. This detection model may serve as the starting point for high throughput of multianalyte assay.Entities:
Year: 2014 PMID: 24756073 PMCID: PMC3996466 DOI: 10.1038/srep04747
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic diagrams of immunosensor array.
(A) preparation procedure of HRP and PtPd-GS labeled redox probe branched antibodies. (B) Schematic illustration of the stepwise immunosensor fabrication process and interaction of antibody-antigen.
Figure 2SEM image of GS(A), GS-Pd NPs (B) and GS-PtPd NPs (C). TEM images of Pd-GN (D)and PtPd-GN at different magnifications (E and F). XPS of GS-PtPd NPs(G), Pd3d region (H).
Figure 3(A) EIS obtained for different modified electrodes in 5.0 mM [Fe(CN)6]3−/4−: (a) bare electrode, (b) AuNPs/bare electrode, (c) Ab1/AuNPs/bare electrode, (d) BSA/Ab1/AuNPs/bare electrode, (e) Ag/BSA/Ab1/AuNPs/bare electrode. (B) Effect of the concentration of H2O2 on the response signals. The insert shows the DPV responds with different concentrations of H2O2. (C) Comparison of the electrocatalytic activities of different labeled probes by chronoamperometry: (a): HRP/Ab2-AQ/PtPd, (b): HRP/Ab2-AQ/PtPd-GS.
Figure 4Typical DPV immunoassay signals for the investigation of cross-reactivity: (a) 2.4 ng mL−1 AFP-L3, (b) 3.2 AU L−1 DCP, (c) 2.4 ng mL−1 AFP-L3 and 3.2 AU L−1 DCP.
Figure 5DPV responses: The curves a, b, c, d, e in Fig. 5 (A) are the corresponding DPV after sandwich format immunoreaction with increasing DCP and AFP-L3 concentrations at 0.0320, 0.320, 1.60, 2.10, 3.20 AU L−1 and 0.0240, 0.240, 1.20, 1.60, 2.40 ng mL−1 respectively. The curves a′, b′, c′, d′, e′ in Fig. 5 (B) are the corresponding DPV after sandwich format immunoreactions with increasing γ-GT and AFU concentrations at 1.00, 2.00, 3.50, 6.00, 9.50 U L−1 and 1.20, 2.40, 4.00, 6.00, 9.00 U L−1 respectively. The curves a″, b″, c″, d″, e″ in Fig. 5 (C) are the corresponding DPV after sandwich format immunoreactions with increasing AFP and AFT concentration 0.0250, 0.250, 1.00, 2.50, 5.00 ng mL−1 and 0.0240, 0.240, 0.960, 4.80, 9.60 ng mL−1 respectively.
Recovery results of the proposed immunosensor in human serum
| Sample | 1 | 2 | 3 | 4 | 5 | |
|---|---|---|---|---|---|---|
| Targe | ||||||
| DCP | Addition | 3.20 | 2.10 | 1.60 | 0.320 | 0.0320 |
| Found | 3.04 | 2.17 | 1.68 | 0.312 | 0.0325 | |
| Recvery (%) | 95.0 | 103 | 105 | 97.5 | 102 | |
| AFP-L3 | Addition | 2.40 | 1.60 | 1.20 | 0.240 | 0.0240 |
| Found | 2.31 | 1.56 | 1.14 | 0.248 | 0.0243 | |
| Recvery (%) | 96.3 | 97.5 | 95.0 | 103 | 101 | |
| AFU | Addition | 9.00 | 6.00 | 4.00 | 2.40 | 1.20 |
| Found | 9.09 | 6.12 | 3.91 | 2.33 | 1.29 | |
| Recvery (%) | 101 | 102 | 97.8 | 97.1 | 108 | |
| γ-GT | Addition | 9.50 | 6.00 | 3.50 | 2.00 | 1.00 |
| Found | 9.45 | 6.10 | 3.52 | 1.96 | 1.08 | |
| Recvery (%) | 99.4 | 102 | 101 | 98.0 | 108 | |
| AFP | Addition | 5.00 | 2.50 | 1.00 | 0.250 | 0.0250 |
| Found | 4.95 | 2.55 | 1.09 | 0.24 | 0.0256 | |
| Recvery (%) | 99.0 | 102 | 109 | 96.0 | 102 | |
| APT | Addition | 9.60 | 4.80 | 0.0960 | 0.240 | 0.0240 |
| Found | 9.71 | 4.78 | 0.090 | 0.243 | 0.0231 | |
| Recvery (%) | 101 | 99.6 | 93.8 | 101 | 96.3 | |
DCP (AU L−1), γ-GT and AFU (U L−1), AFP-L3, AFP and APT (ng mL−1).